USS Investment Management Ltd Has $7.42 Million Position in IQVIA Holdings Inc. $IQV

USS Investment Management Ltd grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 17.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,897 shares of the medical research company’s stock after acquiring an additional 4,807 shares during the period. USS Investment Management Ltd’s holdings in IQVIA were worth $7,418,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of IQV. Vanguard Personalized Indexing Management LLC boosted its position in shares of IQVIA by 4.7% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 32,272 shares of the medical research company’s stock worth $7,274,000 after purchasing an additional 1,435 shares in the last quarter. Verition Fund Management LLC boosted its position in shares of IQVIA by 25.3% during the 4th quarter. Verition Fund Management LLC now owns 22,556 shares of the medical research company’s stock worth $5,084,000 after purchasing an additional 4,557 shares in the last quarter. Panagora Asset Management Inc. boosted its position in shares of IQVIA by 69.8% during the 4th quarter. Panagora Asset Management Inc. now owns 192,780 shares of the medical research company’s stock worth $43,455,000 after purchasing an additional 79,237 shares in the last quarter. Mariner LLC boosted its position in shares of IQVIA by 209.4% during the 4th quarter. Mariner LLC now owns 87,304 shares of the medical research company’s stock worth $19,695,000 after purchasing an additional 59,087 shares in the last quarter. Finally, Focus Partners Wealth boosted its position in shares of IQVIA by 14.0% during the 4th quarter. Focus Partners Wealth now owns 87,596 shares of the medical research company’s stock worth $19,728,000 after purchasing an additional 10,735 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Down 1.9%

NYSE:IQV opened at $178.07 on Tuesday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market cap of $29.72 billion, a price-to-earnings ratio of 22.07, a price-to-earnings-growth ratio of 1.56 and a beta of 1.21. IQVIA Holdings Inc. has a 52 week low of $153.01 and a 52 week high of $247.04. The firm has a 50-day moving average price of $173.65 and a two-hundred day moving average price of $193.06.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter last year, the business posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research report on Friday, March 6th. Royal Bank Of Canada initiated coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective on the stock. Morgan Stanley set a $225.00 price target on shares of IQVIA in a research report on Thursday, May 7th. HSBC set a $210.00 price target on shares of IQVIA in a research report on Wednesday, June 3rd. Finally, Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $224.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.